Article Title: Erlotinib in previously treated non-small-cell lung cancer
Authors: Shepherd, FA;Pereira, JR;Ciuleanu, T;Tan, EH;Hirsh, V;Thongprasert, S;Campos, D;Maoleekoonpiroj, S;Smylie, M;Martins, R;van Kooten, M;Dediu, M;Findlay, B;Tu, DS;Johnston, D;Bezjak, A;Clark, G;Santabarbara, P;Seymour, L;Natl Canc Inst Canada Clin Trials
Journal: N ENGL J MED
Volume: 353
Issue: 2
Page: 123-132
Q：Why do you think your paper is highly cited?
A：This is the first, and, to date, only trial of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor to show a survival advantage for patients with advanced non-small cell lung cancer.
Q：Does it describe a new discovery or a new methodology that's useful to others?
A：Yes, in that this is a new form of treatment that differs from chemotherapy. It is an oral drug, and not associated with many of the side effects of chemotherapy, such as hair loss and falling blood counts.
Q：Could you summarize the significance of your paper in layman's terms?
A：The trial documents a role for relotinib, a well tolerated agent for the treatment of advanced non-small cell lung cancer after chemotherapy has failed to work or stopped working. It provides a new treatment option for patients who previously had no options left. Erlotinib prolongs survival, improves symptoms, and improves quality of life in this particular patient population.
Q：How did you become involved in this research?
A：This trial was led by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). I am the Chair of the Lung Cancer Committee of the NCIC CTG and was the Principal Investigator of the study.
Frances A. Shepherd, M.D., FRCPC
Scott Taylor Chair in Lung Cancer Research
Senior Staff Physician at the Princess Margaret Hospital
Site Group Leader for the Lung Cancer site
Professor of Medicine in the Department of Medicine at the University of Toronto
Toronto, Ontario, Canada
问：为什么您认为你的文章会被高度引用？
答：这是第一次，也是迄今为止唯一的表皮生长因子受体酪氨酸激酶抑制剂的药物临床试验，它显示了晚期非小细胞肺癌患者经过该药治疗能获得更长生存期。
问：论文是否描绘了一个新的发现或者有助于其他学者的新方法？
答：是的，这是一种有别于化学疗法的新的治疗形式。它是一种口服药物，并且没有化疗的许多副作用，比如脱发和血细胞计数减少。
问：您能简要的描述你的论文的重要性吗？
答：这个临床试验证明了relotinib的作用，这是一种耐受性好的抗晚期非小细胞肺癌药物，可用于治疗那些化疗失败或对化疗不再敏感（有效）的患者。这种治疗为已别无选择处于绝望中的患者提供了一种新的治疗方法（和希望）。Erlotini药物能让这种特殊的患者人群延长生存时间，改善症状，并且提高生活质量。
问：您是如何涉足这项研究的？
答：这项试验由加拿大临床试验小组国立癌症研究所（NCIC CTG）领导，我是NCIC CTG中肺癌委员会的会长并且是这个项目的主要研究者。
编辑：西门吹血
